Skip to main content

Advertisement

Table 2 Distribution of antibodies in pre-RA cases stratified by time to RA (dichotomized at median of duration between Ab testing and RA diagnosis, i.e. 7 years). Cut-offs are based on the 98th percentile of controls with the exception of anti-CCP2 antibodies where the manufacturer’s cut-off was applied, and RF where a titre of 1:40 was considered positive. RF; rheumatoid factor. CEP1, cFib and cVim; citrullinated peptides from α-enolase, fibrinogen and vimentin respectively. REP1, Fib and Vim are the arginine-containing control peptides. CPP3 and CPP5 are immunodominant peptides from PPAD, and RPP3 and RPP5 are the arginine-containing control peptides. RgpB; arginine gingipain

From: Smoking, Porphyromonas gingivalis and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case–control study

Antibodies Time to diagnosis  
  Time <7 years n = 51 Time ≥ 7 years n = 52 p-value
RF n (%) 15 (29) 9 (18) 0.179
CCP2 n (%) 15 (27) 10 (20) 0.298
CEP1 n (%) 11 (21) 4 (8) 0.056
REP1 n (%) 2 (4) 0 (0) 0.157
cFib n (%) 13 (25) 6 (12) 0.092
Fib n (%) 1 (2) 1 (2) 0.978
cVim n (%) 4 (10) 1 (3) 0.204
Vim n (%) 3 (6) 1 (2) 0.278
CPP3 n (%) 1 (2) 1 (2) 0.989
RPP3 n (%) 3 (6) 2 (4) 0.663
CPP5 n (%) 2 (4) 3 (6) 0.631
RPP5 n (%) 0 (0) 2 (4) 0.149
RgpB n (%) 2 (4) 1 (2) 0.569
RgpB quartiles
  1 (<1280) 25 (48) 26 (51) 0.571
  2 (≥1280) 17 (33) 12 (24)
  3 (≥2560) 8 (15) 12 (24)
  4 (≥5120) 2 (4) 1 (2)
RgpB (u/ml), median (IQR) 1280 (713–1946) 1174 (468–2560) 0.449